Hans Petter Eikesdal

Hans Petter Eikesdal (HPE) is a consultant medical & radiation oncologist, working in the Dept. of Oncology, Haukeland University Hospital, Bergen, Norway (https://helse-bergen.no/en/avdelinger/kreftbehandling-og-medisinsk-fysik...).

His clinical work is dedicated to patients with breast cancer and malignant melanoma, and he is a member of the executive committee for the Norwegian Breast Cancer Group (https://nbcg.no/about/), setting the national guidelines for treatment of breast cancer in Norway (https://www.helsebiblioteket.no/retningslinjer/brystkreft/forord;jsessio...).

He is a senior researcher in the Bergen Breast Cancer Group, working in the Mohn Cancer Research Laboratory (https://www.uib.no/fg/g18). He is heading a research group studying the molecular characteristics governing resistance to endocrine therapy and chemotherapy in hormone receptor positive breast cancer and chemoresistance in triple negative breast cancer. He is the national coordinating principal investigator of the PETREMAC (ClinicalTrials.gov Identifier: NCT02624973) and p53 breast trials (ClinicalTrials.gov Identifier: NCT02965950), where patients with breast cancer are given personalized cancer therapy, based on the molecular subtype of the tumor. He is heading the Bergen Breast Cancer Group and the K.G. Jebsen Center for genome-directed therapy in cancer (https://stiftkgj.no/what-we-do/k-g-jebsen-centres-of-medical-research/k-g-jebsen-center-for-genom-directed-therapy-in-cancer/?lang=en), together with Professor Per Eystein Lønning and senior researcher Stian Knappskog. 

HPE completed his PhD degree in 2002, with Professor Olav Dahl as the main supervisor. He worked as a postdoctoral fellow at Harvard University, USA, 2007-09 in Professor Raghu Kalluri´s Division of Matrix Biology, and has an ongoing collaboration with Professor Kalluri at his current work site at MD Anderson Cancer Center in Houston, Texas. HPE joined the Bergen Breast Cancer Group in 2009, as a senior researcher. He was employed as Professor in a 20% position at Dept. of Clinical Science, Faculty of Medicine, University of Bergen, from January 2019.